US Stock MarketDetailed Quotes
RAPT RAPT Therapeutics
- 2.340
- +0.070+3.08%
Trading Nov 5 11:19 ET
81.67MMarket Cap-747P/E (TTM)
2.360High2.180Low73.53KVolume2.260Open2.270Pre Close168.86KTurnover0.23%Turnover RatioLossP/E (Static)34.90MShares27.35052wk High0.75P/B73.84MFloat Cap1.64052wk Low--Dividend TTM31.55MShs Float51.210Historical High--Div YieldTTM7.93%Amplitude1.640Historical Low2.296Avg Price1Lot Size
RAPT Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 2.27%-28.15M | -45.60%-27.08M | -37.13%-97.05M | -21.47%-27.75M | -27.61%-21.88M | -89.59%-28.81M | -19.41%-18.6M | -15.97%-70.77M | -10.48%-22.85M | -36.98%-17.15M |
| Net income from continuing operations | -9.43%-27.66M | -4.27%-30.52M | -39.31%-116.8M | -34.53%-30.88M | -47.73%-31.37M | -31.78%-25.28M | -43.01%-29.27M | -21.15%-83.84M | -28.01%-22.95M | -13.85%-21.24M |
| Operating gains losses | ---- | ---- | -204.47%-655K | --0 | --0 | ---- | ---- | 143.02%627K | -282.61%-88K | 111.56%366K |
| Depreciation and amortization | 13.38%305K | 5.02%314K | 16.14%1.22M | 28.17%323K | 25.00%325K | -1.82%269K | 14.56%299K | 5.12%1.05M | 9.09%252K | 13.54%260K |
| Other non cash items | 0.00%584K | 0.00%584K | 32.67%2.34M | 22.18%584K | 36.21%583K | 37.09%584K | 36.45%584K | --1.76M | --478K | --428K |
| Change In working capital | 6.84%-6.02M | -126.30%-1.88M | 511.91%5.5M | 65.98%-990K | 1,745.71%5.81M | -6,423.23%-6.46M | 424.87%7.13M | 68.94%-1.34M | 46.86%-2.91M | -89.60%315K |
| -Change in prepaid assets | 133.96%1.12M | -189.18%-437K | 161.29%871K | 89.55%-223K | -17.33%124K | 633.33%480K | -24.85%490K | 19.44%-1.42M | 0.47%-2.13M | -84.08%150K |
| -Change in payables and accrued expense | -2.85%-6.43M | -110.00%-728K | 97.71%7.34M | 73.00%-71K | 847.70%6.38M | -543.51%-6.25M | 284.82%7.28M | 297.64%3.71M | 89.95%-263K | -78.15%673K |
| -Change in other current liabilities | -3.34%-712K | -12.15%-711K | -29.09%-2.71M | -35.41%-696K | -35.43%-688K | -29.51%-689K | -16.76%-634K | ---2.1M | ---514K | ---508K |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 55.96%-1.53M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 2.27%-28.15M | -45.60%-27.08M | -37.13%-97.05M | -21.47%-27.75M | -27.61%-21.88M | -89.59%-28.81M | -19.41%-18.6M | -15.97%-70.77M | -10.48%-22.85M | -36.98%-17.15M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -40.77%19.21M | -37.23%15.89M | 328.91%104.13M | 150.01%20.64M | 246.31%25.75M | 410.16%32.44M | 6.17%25.31M | 44.08%-45.49M | -159.69%-41.27M | -24.16%-17.6M |
| Net PPE purchase and sale | 100.43%1K | 86.17%-105K | -33.14%-1.13M | -36.73%-67K | 18.52%-66K | 58.83%-233K | -409.40%-759K | -11.92%-845K | 87.56%-49K | -15.71%-81K |
| Net investment purchase and sale | -41.19%19.21M | -38.65%15.99M | 335.77%105.26M | 150.23%20.71M | 247.36%25.82M | 430.27%32.67M | 8.68%26.07M | 44.60%-44.65M | -165.98%-41.22M | -24.21%-17.52M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -40.77%19.21M | -37.23%15.89M | 328.91%104.13M | 150.01%20.64M | 246.31%25.75M | 410.16%32.44M | 6.17%25.31M | 44.08%-45.49M | -159.69%-41.27M | -24.16%-17.6M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -8.60%701K | 7,689.66%9.04M | -98.90%1.45M | -99.39%458K | -97.98%106K | -98.48%767K | -12.12%116K | -7.28%131.18M | 12,438.94%75.36M | 1,012.50%5.25M |
| Net common stock issuance | --0 | --8.97M | --0 | --0 | --0 | --0 | --0 | -6.94%129.79M | 39,806.91%75.03M | --4.98M |
| Proceeds from stock option exercised by employees | -8.60%701K | -42.24%67K | 3.95%1.45M | 37.13%458K | -61.03%106K | 17.28%767K | -12.12%116K | -31.16%1.39M | -19.13%334K | -42.37%272K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -8.60%701K | 7,689.66%9.04M | -98.90%1.45M | -99.39%458K | -97.98%106K | -98.48%767K | -12.12%116K | -7.28%131.18M | 12,438.94%75.36M | 1,012.50%5.25M |
| Net cash flow | ||||||||||
| Beginning cash position | -0.99%45.32M | 21.91%47.48M | 62.09%38.95M | 95.39%54.14M | -12.31%50.16M | 41.18%45.77M | 62.09%38.95M | -3.58%24.03M | -53.82%27.71M | -33.65%57.2M |
| Current changes in cash | -287.44%-8.24M | -131.68%-2.16M | -42.81%8.53M | -159.23%-6.66M | 113.46%3.97M | -82.26%4.4M | -18.70%6.82M | 1,774.41%14.92M | 131.25%11.24M | -12.49%-29.5M |
| End cash Position | -26.09%37.08M | -0.99%45.32M | 21.91%47.48M | 21.91%47.48M | 95.39%54.14M | -12.31%50.16M | 41.18%45.77M | 62.09%38.95M | 62.09%38.95M | -53.82%27.71M |
| Free cash flow | 3.06%-28.15M | -40.43%-27.19M | -37.08%-98.17M | -21.50%-27.82M | -27.39%-21.95M | -84.26%-29.04M | -23.11%-19.36M | -15.92%-71.62M | -8.65%-22.9M | -36.87%-17.23M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data